MONTREAL, Oct. 25 /CNW Telbec/ - Procyon Biopharma Inc. (TSX: PBP) announced today progress for the U.S. dose finding study for PCK3145, its non-toxic therapeutic peptide for the treatment of advanced prostate cancer, and indicated that the study is on track for completion by year end. With four patients remaining to be enrolled in the study, PCK3145 is found to be very well tolerated in all patients treated so far. No side effects have been noted and the data suggests that there is again an impact on the metastatic enzyme, MMP-9 (Matrix Metalloproteinase-9), plasma levels.
